These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 32657776)

  • 1. AGER1 downregulation associates with fibrosis in nonalcoholic steatohepatitis and type 2 diabetes.
    Dehnad A; Fan W; Jiang JX; Fish SR; Li Y; Das S; Mozes G; Wong KA; Olson KA; Charville GW; Ali M; Török NJ
    J Clin Invest; 2020 Aug; 130(8):4320-4330. PubMed ID: 32657776
    [TBL] [Abstract][Full Text] [Related]  

  • 2. AGER1 deficiency-triggered ferroptosis drives fibrosis progression in nonalcoholic steatohepatitis with type 2 diabetes mellitus.
    Gong Y; Liu Z; Zhang Y; Zhang J; Zheng Y; Wu Z
    Cell Death Discov; 2023 Jun; 9(1):178. PubMed ID: 37280194
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The transcription factor c-Jun/AP-1 promotes liver fibrosis during non-alcoholic steatohepatitis by regulating Osteopontin expression.
    Schulien I; Hockenjos B; Schmitt-Graeff A; Perdekamp MG; Follo M; Thimme R; Hasselblatt P
    Cell Death Differ; 2019 Sep; 26(9):1688-1699. PubMed ID: 30778201
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ron Receptor Signaling Ameliorates Hepatic Fibrosis in a Diet-Induced Nonalcoholic Steatohepatitis Mouse Model.
    Allen J; Zhang J; Quickel MD; Kennett M; Patterson AD; Hankey-Giblin PA
    J Proteome Res; 2018 Sep; 17(9):3268-3280. PubMed ID: 30091925
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insulin resistance promotes Lysyl Oxidase Like 2 induction and fibrosis accumulation in non-alcoholic fatty liver disease.
    Dongiovanni P; Meroni M; Baselli GA; Bassani GA; Rametta R; Pietrelli A; Maggioni M; Facciotti F; Trunzo V; Badiali S; Fargion S; Gatti S; Valenti L
    Clin Sci (Lond); 2017 Jun; 131(12):1301-1315. PubMed ID: 28468951
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advanced glycation endproducts induce fibrogenic activity in nonalcoholic steatohepatitis by modulating TNF-α-converting enzyme activity in mice.
    Jiang JX; Chen X; Fukada H; Serizawa N; Devaraj S; Török NJ
    Hepatology; 2013 Oct; 58(4):1339-48. PubMed ID: 23703665
    [TBL] [Abstract][Full Text] [Related]  

  • 7. p16 deficiency promotes nonalcoholic steatohepatitis via regulation of hepatic oxidative stress.
    Lv F; Wu J; Miao D; An W; Wang Y
    Biochem Biophys Res Commun; 2017 Apr; 486(2):264-269. PubMed ID: 28286271
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic Nrf2 Overactivation Inhibits the Deleterious Effects Induced by Hepatocyte-Specific c-met Deletion during the Progression of NASH.
    Ramadori P; Drescher H; Erschfeld S; Fragoulis A; Kensler TW; Wruck CJ; Cubero FJ; Trautwein C; Streetz KL; Kroy DC
    Oxid Med Cell Longev; 2017; 2017():3420286. PubMed ID: 28676836
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatocyte TAZ/WWTR1 Promotes Inflammation and Fibrosis in Nonalcoholic Steatohepatitis.
    Wang X; Zheng Z; Caviglia JM; Corey KE; Herfel TM; Cai B; Masia R; Chung RT; Lefkowitch JH; Schwabe RF; Tabas I
    Cell Metab; 2016 Dec; 24(6):848-862. PubMed ID: 28068223
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Myeloperoxidase-Hepatocyte-Stellate Cell Cross Talk Promotes Hepatocyte Injury and Fibrosis in Experimental Nonalcoholic Steatohepatitis.
    Pulli B; Ali M; Iwamoto Y; Zeller MW; Schob S; Linnoila JJ; Chen JW
    Antioxid Redox Signal; 2015 Dec; 23(16):1255-69. PubMed ID: 26058518
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatocyte-specific sirtuin 6 deletion predisposes to nonalcoholic steatohepatitis by up-regulation of Bach1, an Nrf2 repressor.
    Ka SO; Bang IH; Bae EJ; Park BH
    FASEB J; 2017 Sep; 31(9):3999-4010. PubMed ID: 28536120
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Growth differentiation factor 15 ameliorates nonalcoholic steatohepatitis and related metabolic disorders in mice.
    Kim KH; Kim SH; Han DH; Jo YS; Lee YH; Lee MS
    Sci Rep; 2018 May; 8(1):6789. PubMed ID: 29717162
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cholesterol Induces Nrf-2- and HIF-1
    Kaminsky-Kolesnikov Y; Rauchbach E; Abu-Halaka D; Hahn M; García-Ruiz C; Fernandez-Checa JC; Madar Z; Tirosh O
    Oxid Med Cell Longev; 2020; 2020():5393761. PubMed ID: 32566088
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RAGE deficiency does not affect non-alcoholic steatohepatitis and atherosclerosis in Western type diet-fed Ldlr
    Bijnen M; Beelen N; Wetzels S; Gaar JV; Vroomen M; Wijnands E; Scheijen JL; van de Waarenburg MPH; Gijbels MJ; Cleutjens JP; Biessen EAL; Stehouwer CDA; Schalkwijk CG; Wouters K
    Sci Rep; 2018 Oct; 8(1):15256. PubMed ID: 30323247
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dietary advanced glycation end-products aggravate non-alcoholic fatty liver disease.
    Leung C; Herath CB; Jia Z; Andrikopoulos S; Brown BE; Davies MJ; Rivera LR; Furness JB; Forbes JM; Angus PW
    World J Gastroenterol; 2016 Sep; 22(35):8026-40. PubMed ID: 27672297
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High Mobility Group Box-1 Drives Fibrosis Progression Signaling via the Receptor for Advanced Glycation End Products in Mice.
    Ge X; Arriazu E; Magdaleno F; Antoine DJ; Dela Cruz R; Theise N; Nieto N
    Hepatology; 2018 Dec; 68(6):2380-2404. PubMed ID: 29774570
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exendin-4, a glucagon-like peptide-1 receptor agonist downregulates hepatic receptor for advanced glycation end products in non-alcoholic steatohepatitis rat model.
    Allam MM; El Gazzar WB
    Arch Physiol Biochem; 2018 Feb; 124(1):10-17. PubMed ID: 28696785
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibiting Interleukin 11 Signaling Reduces Hepatocyte Death and Liver Fibrosis, Inflammation, and Steatosis in Mouse Models of Nonalcoholic Steatohepatitis.
    Widjaja AA; Singh BK; Adami E; Viswanathan S; Dong J; D'Agostino GA; Ng B; Lim WW; Tan J; Paleja BS; Tripathi M; Lim SY; Shekeran SG; Chothani SP; Rabes A; Sombetzki M; Bruinstroop E; Min LP; Sinha RA; Albani S; Yen PM; Schafer S; Cook SA
    Gastroenterology; 2019 Sep; 157(3):777-792.e14. PubMed ID: 31078624
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antifibrotic effect of pirfenidone in a mouse model of human nonalcoholic steatohepatitis.
    Komiya C; Tanaka M; Tsuchiya K; Shimazu N; Mori K; Furuke S; Miyachi Y; Shiba K; Yamaguchi S; Ikeda K; Ochi K; Nakabayashi K; Hata KI; Itoh M; Suganami T; Ogawa Y
    Sci Rep; 2017 Mar; 7():44754. PubMed ID: 28303974
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protective effect of isochlorogenic acid B on liver fibrosis in non-alcoholic steatohepatitis of mice.
    Liu X; Huang K; Niu Z; Mei D; Zhang B
    Basic Clin Pharmacol Toxicol; 2019 Feb; 124(2):144-153. PubMed ID: 30180301
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.